| JNPMEDI Business Development (BD) Team - Strengthening Sales with Industry Experts… Aiming to Expand Domestic Market Reach and Lay the Foundation for Global Expansion
| Proactive Communication and Collaboration Utilizing Industry Expertise… Positioning JNPMEDI as a Leading Company in Domestic Clinical Trial Trends
| ‘BD Networking Day’ on March 15 - A Platform for Industry Professionals to Engage and Share Insights
| Hyungjun Kim, BD Team Leader Emphasizes “boosting domestic sales and securing global market competitiveness.”
JNPMEDI, a medical data platform company, announced on the 28th its plan to expand its BD team with experts from various fields within the clinical industry, driving significant sales growth.
Leading the digital transformation in the clinical trial industry through the 'Maven Clinical Cloud,' JNPMEDI is committed to enhancing its sales capabilities by aggressively recruiting talents and expanding its BD team. This expansion aims to broaden domestic market reach and set the stage for global expansion.
With an industry-leading workforce, JNPMEDI's BD team includes seasoned professionals such as △Jingon Kim, Director from Asan Medical Center, DreamCIS, and SeoulCRO, △Hyungjun Kim, Team Leader with over 10 years of experience at Johnson & Johnson Medical, △Junhyuk Lim, Manager formerly with Samsung Bioepis Global Alliance, △Soohwan Kim, Manager with CRO BD experience from LSK Global PS.
The BD team is based in a dedicated office space at Seoul Mapo Frontone, focusing on professional interactions and collaborations with key stakeholders in the clinical industry, such as medical institutions, pharmaceutical companies, and CROs. By understanding field requirements and applying them to solution enhancement and business diversification, JNPMEDI aims to improve customer benefits. The recruitment of experienced professionals in various clinical fields also aims to expand domestic and global businesses and effectively respond to complex clinical trials such as oncology research.
Additionally, JNPMEDI will host a 'BD Networking Day' on March 15 at the Mapo Frontone 3rd floor conference room. This event will provide a platform for clinical industry professionals to engage in active information exchange, business collaboration opportunities, and in-depth academic discussions to promote healthy growth and development in the domestic and international clinical trial markets. This event is targeted at BD professionals from CRO companies, with plans to regularly hold such gatherings to enhance industry communication and ecosystem expansion.
Hyungjun Kim, BD Team Leader, stated, "JNPMEDI aims to accelerate the digital transformation of the domestic clinical trial market through active communication with customers, positioning itself as a leading company in clinical trial trends. We will continue to enhance the 'Maven Clinical Cloud' to maximize clinical trial efficiency, increase domestic sales, and establish a foundation for global expansion to secure market competitiveness."
Founded in 2020, JNPMEDI seeks to innovate the clinical trial industry with digital technology. The company's 'Maven Clinical Cloud' solution, applicable to various medical fields such as pharmaceuticals, biotechnology, digital therapeutics, and digital medical devices, is recognized as a new alternative leading the advancement of the domestic Decentralized Clinical Trials (DCT) market.
| JNPMEDI Business Development (BD) Team - Strengthening Sales with Industry Experts… Aiming to Expand Domestic Market Reach and Lay the Foundation for Global Expansion
| Proactive Communication and Collaboration Utilizing Industry Expertise… Positioning JNPMEDI as a Leading Company in Domestic Clinical Trial Trends
| ‘BD Networking Day’ on March 15 - A Platform for Industry Professionals to Engage and Share Insights
| Hyungjun Kim, BD Team Leader Emphasizes “boosting domestic sales and securing global market competitiveness.”
JNPMEDI, a medical data platform company, announced on the 28th its plan to expand its BD team with experts from various fields within the clinical industry, driving significant sales growth.
Leading the digital transformation in the clinical trial industry through the 'Maven Clinical Cloud,' JNPMEDI is committed to enhancing its sales capabilities by aggressively recruiting talents and expanding its BD team. This expansion aims to broaden domestic market reach and set the stage for global expansion.
With an industry-leading workforce, JNPMEDI's BD team includes seasoned professionals such as △Jingon Kim, Director from Asan Medical Center, DreamCIS, and SeoulCRO, △Hyungjun Kim, Team Leader with over 10 years of experience at Johnson & Johnson Medical, △Junhyuk Lim, Manager formerly with Samsung Bioepis Global Alliance, △Soohwan Kim, Manager with CRO BD experience from LSK Global PS.
The BD team is based in a dedicated office space at Seoul Mapo Frontone, focusing on professional interactions and collaborations with key stakeholders in the clinical industry, such as medical institutions, pharmaceutical companies, and CROs. By understanding field requirements and applying them to solution enhancement and business diversification, JNPMEDI aims to improve customer benefits. The recruitment of experienced professionals in various clinical fields also aims to expand domestic and global businesses and effectively respond to complex clinical trials such as oncology research.
Additionally, JNPMEDI will host a 'BD Networking Day' on March 15 at the Mapo Frontone 3rd floor conference room. This event will provide a platform for clinical industry professionals to engage in active information exchange, business collaboration opportunities, and in-depth academic discussions to promote healthy growth and development in the domestic and international clinical trial markets. This event is targeted at BD professionals from CRO companies, with plans to regularly hold such gatherings to enhance industry communication and ecosystem expansion.
Hyungjun Kim, BD Team Leader, stated, "JNPMEDI aims to accelerate the digital transformation of the domestic clinical trial market through active communication with customers, positioning itself as a leading company in clinical trial trends. We will continue to enhance the 'Maven Clinical Cloud' to maximize clinical trial efficiency, increase domestic sales, and establish a foundation for global expansion to secure market competitiveness."
Founded in 2020, JNPMEDI seeks to innovate the clinical trial industry with digital technology. The company's 'Maven Clinical Cloud' solution, applicable to various medical fields such as pharmaceuticals, biotechnology, digital therapeutics, and digital medical devices, is recognized as a new alternative leading the advancement of the domestic Decentralized Clinical Trials (DCT) market.